课题基金 / 基金详情

项目摘要

项目成果

KATHLEEN E. RODGERS的其他基金

相似基金

相关文献

中文摘要
翻译
免疫抑制的分子机制,由两个杂质中, 有机磷农药马拉硫磷、乙酰甲胺磷和杀螟松, O,O,S-三甲基硫代磷酸酯(OOS-TMP)和O,S,S-三甲基 二硫代磷酸酯,将被检查。 巨噬细胞,通过细胞 分离和重组实验,已被证明是 受OOS-TMP处理影响最大的淋巴样细胞。 中的阻塞 巨噬细胞的成熟,这发生在急性施用 将确定OOS-TMP。 研究将包括巨噬细胞 细胞表面标志物Ia、Mac-1、Mac-2和F4/80,功能活性和 分泌产物 结构类似物OSS-TMP的抑制作用 对细胞溶解效应器功能的影响将使用 功能上确定的细胞毒性T淋巴细胞(CTL)和其他细胞溶解性T淋巴细胞(CTL), 效应细胞 阻断鼠CTL功能的位点将是 使用缀合物形成和Ca 2+脉冲技术测定。 的 将使用放射性标记的OSS-TMP鉴定分子位点, 生化分析 此外,还改进了比色测定法, (dye将研究其适用性 作为细胞毒性和细胞抑制活性的筛选试验, 环境毒物 该测定可作为标准品的替代品 台盼蓝排除法用于评估细胞活力。
英文摘要
The molecular mechanisms of immune suppression by two impurities in the organosphosphate pesticides, malathion, acephate and fenitrothion, O,O,S-trimethyl phosphorothioate (OOS-TMP) and O,S,S-trimethyl phosphorodithioate, will be examined. Macrophaages, through cell separation and reconstitution experiments, have been shown to be the lymphoid cell most affected by OOS-TMP treatment. The blockage in the maturation of macrophages which occurs following acute administration of OOS-TMP will be identified. Studies will include changes in macrophage cell surface markers, Ia, Mac-1, Mac-2 and F4/80, functional activity and secretory products. The inhibitory effect of a structural analog OSS-TMP on cytolytic effector function will be examined in detail using functionally defined cytotoxic T lymphocytes (CTL) and other cytolytic effector cells. The site(s) of the blockade of murine CTL function will be determined using conjugate formation and Ca2+ pulse techniques. The molecular sites will be identified using radiolabelled OSS-TMP and biochemical analyses. In addition, an adaptation of a colorimetric assay (dye reduction) for cell viability will be investigated for its suitability as a screening assay for the cytotoxic and cytostatic activities of environmental toxicants. This assay may be an alternative to the standard trypan blue exclusion method for assessing cell viability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
  • 批准号:
    10530821
  • 项目类别:
  • 资助金额:
    $38.38万
  • 财政年份:
    2020
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
  • 批准号:
    10396541
  • 项目类别:
  • 资助金额:
    $151.56万
  • 财政年份:
    2020
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
IND Enabling Studies for RASRx 1902, a novel Mas receptor agonist, for treatment of cognitive impairment in patients at risk for Alzheimer's disease.
  • 批准号:
    10644987
  • 项目类别:
  • 资助金额:
    $152.86万
  • 财政年份:
    2020
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
A(1-7)-Mediated Mitigation of Radiation Induced Thrombocytopenia
  • 批准号:
    8058309
  • 项目类别:
  • 资助金额:
    $43.16万
  • 财政年份:
    2010
  • 负责人:
    KATHLEEN E. RODGERS
  • 依托单位:
海外基金